FDA Approved for RRMM: Kyprolis (carfilzomib) + Revlimid (lenalidomide) and Dexamethasone (KRd)
NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)
FDA Approved for RRMM: Daratumumab (Darzalex)
FDA Approved for NDMM: Lenalidomide (Revlimid)
Myeloma Canada: Patient Handbook - Understanding Your Blood and Blood Tests
Myeloma UK - Myeloma Animations Series: Clonal evolution: the changing nature of myeloma
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
FDA Approved for RRMM: Pomalidomide (Pomalyst) + Dexamethasone
NCT02519452: Phase 1 - Daratumumab + Recombinant Human Hyaluronidase (rHuPH20) RRMM - PAVO Study
NCT02546167: Phase 1 - CART-BCMA Cells for Multiple Myeloma
Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
NCT02412878: Phase 3 - Once-weekly vs Twice-weekly Carfilzomib With Dexa in Relapsed MM (ARROW)
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
NCT02514239: Phase 1 - Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Myeloma Patients
NCT02076009: Phase 3 - Daratumumab, Lenalidomide & Dex (DRd) VS Len & Dexa (Rd) - MMY3003 (POLLUX)
Myeloma UK - Myeloma Animations Series: High Dose Therapy and Autologous Stem Cell Transplantation
14th International Myeloma Workshop: April 3rd-7th, 2013 Kyoto, Japan
Charlotte Radiology: Port Placement: Dr. Eric Wang
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
NCT02119468: Phase 1/2: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With RRMM
NCT02064387: Phase 1 -Safety Pharm.kinetics Pharm.dynamics Img. & Cl. Activity GSK2857916 - DREAMM-1
Myeloma UK - Myeloma Animations Series: Myeloma Kidney Disease
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma